Neurocrine price target raised to $152 from $137 at UBS

UBS raised the firm’s price target on Neurocrine (NBIX) to $152 from $137 and keeps a Buy rating on the shares. Neurocrine’s print should rest the crowded bear case into the quarter and remove a key overhang for the stock, and believes the shares will be “particularly attractive” from here, the analyst tells investors in a research note. UBS says the Ingrezza growth narrative is now re-established, and its analysis suggests Crenessity peak sales of $2.5B.